View in EDS

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

Saved in:
Bibliographic Details
Title: Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Authors: IIIBurris, Howard A1,2, Flinn, Ian W1,2, Patel, Manish R1,3, Fenske, Timothy S4, Deng, Changchun5, Brander, Danielle M6, Gutierrez, Martin7, Essell, James H8, Kuhn, John G9, Miskin, Hari P10, Sportelli, Peter10, Weiss, Michael S10, Vakkalanka, Swaroop11, Savona, Michael R12, O'Connor, Owen A5 owenoconnor@columbia.edu, Burris, Howard A 3rd13, O'Connor, Owen A5
Source: Lancet Oncology. Apr2018, Vol. 19 Issue 4, p486-496. 11p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 128719907
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22IIIBurris%2C+Howard+A%22">IIIBurris, Howard A</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Flinn%2C+Ian+W%22">Flinn, Ian W</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Patel%2C+Manish+R%22">Patel, Manish R</searchLink><relatesTo>1,3</relatesTo><br /><searchLink fieldCode="AR" term="%22Fenske%2C+Timothy+S%22">Fenske, Timothy S</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Deng%2C+Changchun%22">Deng, Changchun</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Brander%2C+Danielle+M%22">Brander, Danielle M</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Gutierrez%2C+Martin%22">Gutierrez, Martin</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Essell%2C+James+H%22">Essell, James H</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Kuhn%2C+John+G%22">Kuhn, John G</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Miskin%2C+Hari+P%22">Miskin, Hari P</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Sportelli%2C+Peter%22">Sportelli, Peter</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Weiss%2C+Michael+S%22">Weiss, Michael S</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Vakkalanka%2C+Swaroop%22">Vakkalanka, Swaroop</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Savona%2C+Michael+R%22">Savona, Michael R</searchLink><relatesTo>12</relatesTo><br /><searchLink fieldCode="AR" term="%22O'Connor%2C+Owen+A%22">O'Connor, Owen A</searchLink><relatesTo>5</relatesTo><i> owenoconnor@columbia.edu</i><br /><searchLink fieldCode="AR" term="%22Burris%2C+Howard+A+3rd%22">Burris, Howard A 3rd</searchLink><relatesTo>13</relatesTo><br /><searchLink fieldCode="AR" term="%22O'Connor%2C+Owen+A%22">O'Connor, Owen A</searchLink><relatesTo>5</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet+Oncology%22">Lancet Oncology</searchLink>. Apr2018, Vol. 19 Issue 4, p486-496. 11p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=128719907
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(18)30082-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 486
    Titles:
      – TitleFull: Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: IIIBurris, Howard A
      – PersonEntity:
          Name:
            NameFull: Flinn, Ian W
      – PersonEntity:
          Name:
            NameFull: Patel, Manish R
      – PersonEntity:
          Name:
            NameFull: Fenske, Timothy S
      – PersonEntity:
          Name:
            NameFull: Deng, Changchun
      – PersonEntity:
          Name:
            NameFull: Brander, Danielle M
      – PersonEntity:
          Name:
            NameFull: Gutierrez, Martin
      – PersonEntity:
          Name:
            NameFull: Essell, James H
      – PersonEntity:
          Name:
            NameFull: Kuhn, John G
      – PersonEntity:
          Name:
            NameFull: Miskin, Hari P
      – PersonEntity:
          Name:
            NameFull: Sportelli, Peter
      – PersonEntity:
          Name:
            NameFull: Weiss, Michael S
      – PersonEntity:
          Name:
            NameFull: Vakkalanka, Swaroop
      – PersonEntity:
          Name:
            NameFull: Savona, Michael R
      – PersonEntity:
          Name:
            NameFull: O'Connor, Owen A
      – PersonEntity:
          Name:
            NameFull: Burris, Howard A 3rd
      – PersonEntity:
          Name:
            NameFull: O'Connor, Owen A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: Apr2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 14702045
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Lancet Oncology
              Type: main
ResultId 1